Stay updated on Dupilumab in AFRS Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in AFRS Clinical Trial page.

Latest updates to the Dupilumab in AFRS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record now presents details of the completed Phase 3 dupilumab trial for allergic fungal rhinosinusitis, including eligibility, study design, outcomes, and results-related resources. It also includes study documents, a publication, and information about participant-data sharing.SummaryDifference81%

- Check15 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0; the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA sitewide NIH banner announces updates and FAQs about using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check29 days agoChange DetectedThe clinical trial details have been replaced by a 403 Forbidden message, leaving the study record unavailable on the page.SummaryDifference19%

- Check36 days agoChange DetectedThe ClinicalTrials.gov record for the dupilumab study in allergic fungal rhinosinusitis is displayed, including its eligibility criteria, study design, outcome measures, locations, and supporting documents.SummaryDifference82%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study details and navigation with an access-denied screen. This indicates a server-side access issue or restriction that prevents users from viewing the trial record.SummaryDifference19%

Stay in the know with updates to Dupilumab in AFRS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in AFRS Clinical Trial page.